For small-animal perioperative reversal of non-depolarising neuromuscular blockade, neostigmine methylsulfate is formulated as a preservative-free or preserved sterile injection at a concentration of 1.0 mg/mL calculated as neostigmine base. The formulation is prepared in Water for Injection (WFI) equilibrated to 20–25°C under nitrogen blanketing; sodium chloride is added at 9.0 mg/mL to achieve isotonicity, and pH is adjusted to 4.5–6.5 with 0.1 N hydrochloric acid or sodium hydroxide. Each millilitre of finished solution contains neostigmine methylsulfate equivalent to 1.0 mg neostigmine base, with WFI q.s. ad 1.0 mL. Compliance is anchored to USP <1> Injections, USP <85> Bacterial Endotoxins Test, USP <790> Visible Particulates in Injections, USP <788> Particulate Matter in Injections, and ICH Q6A universal test requirements; the API must also satisfy residual solvent limits in USP <467> and elemental impurity criteria in USP <232> and ICH Q3D. The downstream production process begins with API dissolution in approximately 80% of the final WFI volume at 20–25°C under low-speed impeller agitation at 50–100 rpm to avoid foaming. The solution is then brought to final volume and passed through a 0.45 µm clarifying filter before sterile filtration through a 0.22 µm PVDF or PES membrane housed in a steam-sterilised filter assembly. Filter integrity is verified by pre-use water intrusion or bubble point testing and post-use diffusion testing according to PDA Technical Report 26. Aseptic filling into Type I borosilicate glass vials is performed on a peristaltic or rotary piston filling line with inert gas blanketing; fill volume accuracy is maintained within ±2% of target. After filling, vials are stoppered with chlorobutyl rubber closures and sealed with aluminium flip-off caps; an overfill of 5% is commonly applied to compensate for needle-retained volume. Terminal finished products include 1 mL single-dose ampoules, 10 mL multi-dose vials containing a validated preservative system, and 2 mL single-use vials for small dogs and cats. For multi-dose presentations, antimicrobial effectiveness is demonstrated according to USP <51>, and in-use stability after first stopper penetration is limited to 28 days at 2–8°C unless an extended period is validated under ICH Q1A(R2) intermediate storage conditions. Terminal steam sterilisation is avoided because neostigmine methylsulfate undergoes hydrolytic degradation of the carbamate ester at sustained temperatures above 60°C; light protection is required with amber glass or opaque secondary packaging because the compound is photolabile. Filling suites use barrier isolator or restricted access barrier system technology with continuous viable and non-viable particulate monitoring under EU GMP Annex 1 Grade A conditions. Production-scale bottleneck data from aseptic lines indicate maximum fill speeds of 80–120 vials/min for 2 mL formats when 100% in-line checkweighing and nitrogen inertisation are used; higher speeds reduce stoppering consistency and increase glass particulate generation. Batch homogeneity is verified by in-line spectrophotometric or HPLC assay of filled units, with acceptance limits of 95.0–105.0% of labelled content. Endotoxin control relies on WFI system validation at ≤0.25 EU/mL, depyrogenation of glass vials at 250°C for at least 30 min, and validated cleaning of filter housings. The final product is released after sterility testing per USP <71> with a 14-day incubation period. Cleaning validation follows 21 CFR 211.67, and in-process testing is governed by 21 CFR 211.110. Published data for this specific neostigmine injection configuration in veterinary use are consistent with long-standing pharmacopoeial monographs for human presentations; species-specific bioequivalence data are typically not required for a solution dosage form, and the manufacturer may replace comparative bioavailability studies with dissolution or drug-release tests as permitted under VICH GL52. The sub-visible particulate limit is not more than 6000 particles per container for ≥10 µm and not more than 600 particles per container for ≥25 µm under USP <788>. The API should be stored at 2–8°C if long-term retention samples indicate hygroscopic mass gain above 0.5% w/w at 60% RH.

Why Do Equine Hospitals Dilute Neostigmine Methylsulfate Before Intravenous Infusion?

Equine postoperative ileus and gastrointestinal stasis protocols use neostigmine methylsulfate as a dilute intravenous infusion rather than a concentrated bolus to reduce the risk of cholinergic crisis. The manufactured veterinary injection is supplied as a 2.0 mg/mL neostigmine methylsulfate solution in 20 mL or 50 mL multi-dose vials; the hospital admixture step then dilutes this solution to 0.01–0.04 mg/mL in 0.9% sodium chloride. Each 1000 mL infusion therefore contains 10–40 mg of neostigmine methylsulfate, representing a downstream dilution factor of 50:1 to 200:1. Compliance for the finished vial is derived from the same parenteral requirements as small-animal injections, including USP <1>, USP <85>, USP <790>, and EU GMP Volume 4 Annex 4 for veterinary medicinal products; hospital admixture is performed under USP <797> when compounded sterile preparations are produced. The production process for the pre-dilution vial requires higher fill-volume accuracy because downstream dilution magnifies filling error: a deviation of ±0.1 mL in a 20 mL fill changes final admixture concentration by ±5%. Aseptic filling of 20 mL and 50 mL containers typically operates at 40–60 units/min because larger liquid volumes increase splashing and foaming during piston filling. Vial stoppering uses a vacuum-assisted rotating starwheel to limit particulate generation, and stopper seating height is checked with a precision probe to prevent lip rolling. The undiluted injection is adjusted to pH 5.0–6.5; hospital dilution is completed within 4 h of first stopper puncture to avoid preservative depletion. Terminal finished products include 25 mL multi-dose vials labelled for equine hospital use, 50 mL bulk vials intended for closed-system transfer devices, and 50 mL intravenous infusion bags prepared aseptically in the hospital pharmacy. In-use stability after first puncture is limited to 28 days at 2–8°C; repeated needle puncture beyond 10 openings may compromise sterility unless a closed-system transfer device is used. The diluted infusion is administered over 1–2 min for bolus use or as a constant-rate infusion at 0.002 mg/kg/h when prolonged prokinetic effect is required; typical adult horse protocols use 0.01–0.02 mg/kg intravenously repeated at 8-hour intervals under continuous ECG monitoring. Operational boundaries include incompatibility with alkaline solutions and oxidising agents; neostigmine should not be mixed with sodium bicarbonate or barbiturate preparations in the same infusion line. Published compatibility data for neostigmine in PVC infusion bags are limited; polysulfone or polyolefin containers are preferred to minimise sorption and partitioning loss. The label must state that treated horses must not enter the human food chain unless maximum residue limit and withdrawal period data are established in the importing jurisdiction. Freeze-thaw cycling is not recommended; accidental freezing may precipitate the methylsulfate salt. The preservative system must be validated according to USP <51>, but preservative concentration must not exceed levels shown to produce haemolysis on intravenous administration. Process validation for 20 mL multi-dose vials includes three media fill runs at 3000–5000 units per run with no growth in all units; filtration train bacterial endotoxin challenge tests are performed to demonstrate retention and absence of breakthrough. Published data for this specific hospital-diluted configuration are limited; clinical protocols vary between institutions, and the manufacturer should not assign fixed infusion rates on the label unless a target-species pharmacokinetic study has been completed.

Direct Compression of Neostigmine Bromide Tablets at the 15 mg Dose Strength

Neostigmine bromide is the salt form selected for oral solid dosage because it is less hygroscopic than the methylsulfate salt and permits direct compression at low dose strength. The tableting formulation incorporates 15 mg neostigmine bromide per tablet with lactose monohydrate or a 1:1 lactose/microcrystalline cellulose mix as filler; croscarmellose sodium at 2–3% w/w as superdisintegrant; colloidal silicon dioxide at 0.25–0.5% w/w as glidant; and magnesium stearate at 0.5% w/w as lubricant. The total core weight is typically 120–150 mg, yielding a batch addition ratio of 10–12.5% API depending on final tablet mass. Compliance for release testing includes USP <905> Uniformity of Dosage Units, USP <711> Dissolution, USP <1216> Tablet Friability, and assay by HPLC following the pharmacopoeial monograph for Neostigmine Bromide Tablets; the API itself must conform to residual solvent limits under USP <467> and elemental impurity criteria under USP <232> and ICH Q3D. Finished product testing and release fall under 21 CFR 211.165. Blend mixing is performed in a bin blender or V-blender with an intensifier bar at 15–20 rpm for 15–20 min after a pre-blend step in which the API is geometrically diluted with one-third of the filler to reduce segregation of a low-mass active. The direct compression process runs at 20–25°C and ≤40% RH; relative humidity above 60% causes neostigmine bromide to gain mass and adhere to tooling, increasing weight variability. Compression is executed on a rotary tablet press with turret speed of 30–60 rpm, pre-compression force of 2–4 kN, and main compression force of 8–15 kN; target hardness is 50–80 N with friability ≤1.0% after 100 rotations. Dissolution testing uses USP <711> Apparatus 2 at 50 rpm with 900 mL purified water at 37±0.5°C; an acceptance criterion of ≥75% released in 30 min is typically set for immediate-release tablets, although the exact Q value depends on the approved regulatory dossier. Terminal finished product types include 15 mg scored tablets in 30-count and 100-count HDPE bottles with child-resistant closures and a desiccant canister; cold-form aluminium/aluminium blisters are used for tropical climates because of moisture protection. The primary operational boundary is that neostigmine bromide tablets should not be wet-granulated unless absolutely necessary; aqueous granulation can accelerate degradation of the quaternary ammonium salt and reduce assay to below 95% if drying is not completed within 30–60 min at 40°C. If granules are required, non-aqueous granulation with isopropyl alcohol or dry granulation by slugging is preferred. Batch-to-batch variance in API particle size influences content uniformity in low-dose direct compression; API with D90 above 250 µm may require screening through a 250 µm sieve before blending. Tablet splitting is not recommended for doses below 7.5 mg because the API is distributed throughout the tablet mass and splitting may cause dose variation exceeding the 85–115% individual content uniformity limit; compounded capsules or oral liquids are preferable for lower doses. Stability is assessed under ICH Q1A(R2) storage conditions; retained samples are tested at 25°C/60% RH for at least 12 months and at 40°C/75% RH for 6 months in accelerated chambers. Photostability is tested under ICH Q1B; primary containers are chosen to limit light-induced degradation of the carbamate group.

Where repeated tablet administration is not feasible because of patient weight below 5 kg or because dysphagia accompanies myasthenia gravis, neostigmine bromide is prepared as a compounded oral solution or suspension for dose titration in feline and canine patients. The most common working concentration is 2.0 mg/mL neostigmine bromide in purified water, preserved with sodium benzoate at 1.0 mg/mL and adjusted to pH 5.0–5.5 with anhydrous citric acid; a viscosity-enhancing vehicle such as Ora-Plus or a 1% methylcellulose gel may be incorporated when the preparation is dispensed as an oral suspension, but the aqueous solubility of neostigmine bromide favours a true solution. The addition ratio is 0.2% w/v active API, providing a practical dosing volume of 0.05–0.1 mL/kg for typical canine and feline maintenance protocols. Compliance for non-sterile compounding is derived from USP <795> Pharmaceutical Compounding—Nonsterile Preparations and, where the product is distributed as a manufactured veterinary product rather than an extemporaneous prescription, from EU GMP Part II and ICH Q7; antimicrobial effectiveness is verified under USP <51> when a preservative is present, and the final preparation is tested for pH, clarity, and assay. The compounding process begins with weighing neostigmine bromide on an analytical balance with ±0.1 mg readability; the API is dissolved in approximately 70% of the final volume of purified water at 20–25°C with magnetic stirring at 200–300 rpm for 5–10 min. Preservatives and buffer salts are added next, followed by q.s. to volume and filtration through a 10 µm polypropylene clarifying filter. The liquid is packaged in amber PET or glass bottles with child-resistant caps and a calibrated oral syringe; beyond-use dates are assigned according to USP <795> default for preserved aqueous oral liquids, which is 35 days at controlled room temperature or 90 days at refrigerated temperature when a stability-specific study is not available. For unpreserved preparations, the beyond-use date is limited to 14 days at 2–8°C. Terminal finished product types include 30 mL, 60 mL, and 100 mL oral liquids labelled with concentration per millilitre and a graduated dosing syringe. The main operational boundary is chemical instability at alkaline pH; the solution must not be buffered above pH 6.0 because hydrolysis of the carbamate ester accelerates rapidly, and combinations with strongly oxidising agents, alkaline salts, or activated charcoal should be avoided. Light protection is required because neostigmine bromide in aqueous solution shows greater photolability than the dry powder. The production environment should maintain ≤60% RH during weighing to prevent electrostatic drift and moisture absorption. Analytical release includes HPLC assay with acceptance limits of 90.0–110.0% for compounded preparations, absence of visible precipitate, and viscosity measurement for suspension forms. Published data for this specific concentration of neostigmine bromide oral liquid in veterinary compounding are limited; long-term stability beyond 90 days should not be claimed without multi-point chemical and physical stability studies under the intended container closure system.

When Tablet Splitting Falls Below the Therapeutic Window, Compounded Capsules Are Prepared from Neostigmine Bromide Triturations

Compounded capsules are produced for dogs and cats that require dose strengths below the commercially available 15 mg tablet or where splitting of tablet halves creates unacceptable dose variance. The formulation begins with a 1:10 (w/w) trituration of neostigmine bromide in lactose monohydrate prepared by geometric dilution in a porcelain mortar or a V-shell blender; final capsule strengths commonly range from 1 mg to 5 mg neostigmine bromide, with total fill weight adjusted to 100–150 mg using microcrystalline cellulose or mannitol. The addition ratio in the final blend is therefore 0.7–5.0% w/w active API depending on capsule strength. Compliance for non-sterile compounding is governed by USP <795>, with capsule content uniformity evaluated according to USP <905> adapted for compounded preparations, and mass variation checked against the applicable pharmacopoeial general chapter; the source API must comply with ICH Q7 and the veterinary pharmacopoeial monograph for neostigmine bromide. The downstream process involves first blending the trituration with diluent in a low-shear V-blender at 25 rpm for 10–15 min, then adding 0.5% w/w magnesium stearate as a lubricant for an additional 3–5 min. The powder blend is filled into size 3 or 4 HPMC capsule bodies using a manual capsule filling machine for small batches or an intermittent-motion dosator capsule filler for larger batch runs; fill weight uniformity is monitored by in-process checkweighing with ±2 mg acceptance limits. Empty capsule moisture content should be below 5% and the filling suite maintained at ≤40% RH to prevent powder sticking; HPMC capsules are preferred for low-moisture fillers but exhibit higher static charge than gelatin. Terminal finished products are 30-count and 100-count amber vials with desiccant, labelled with individual capsule strength and a beyond-use date of 180 days at 20–25°C in the original container if supported by a long-term stability study; otherwise a conservative beyond-use date is assigned according to USP <795> for non-aqueous solid compounded preparations. Granules can be prepared by wet granulation with 10% w/w povidone K30 in isopropyl alcohol, dried at 40°C until loss on drying is ≤2%, and filled into sachets or capsules; however, dry powder trituration is preferred because neostigmine bromide is water-soluble and granulation liquid can cause localised API migration to granule surfaces. The primary operational boundary is that neostigmine bromide powder is highly potent and requires dedicated weighing areas with segregated utensils; cross-contamination control follows ISPE Risk-MaPP principles with swab limits established from permitted daily exposure estimates. Feed premix for food-producing species is not a valid industrial application for this API in many jurisdictions because maximum residue limits have not been established and the narrow therapeutic index creates risk of overdose with in-feed administration; therefore, the capsule/powder route is restricted to non-food companion animals. Batch-to-batch variance in trituration homogeneity is controlled by passing the final blend through a 250 µm sieve and resampling from 10 positions in the blender; acceptance for blend uniformity is 90.0–110.0% of target with RSD ≤5.0%. The final capsule assay is performed by HPLC with a linear calibration from 0.5 µg/mL to 50 µg/mL, and dissolution is not routinely required for compounded capsules unless the regulatory submission requires an in vitro release test. Published data for this specific configuration are limited; compounding pharmacies rely on API stability data and master formulation records rather than on commercial neostigmine capsule monographs.